Pfizer clinches approximately $10 billion deal to acquire Metsera, outbidding Novo Nordisk

Pfizer has sealed a takeover of obesity drug developer Metsera in a deal valued at up to around $10 billion, edging out rival Novo Nordisk after a heated bidding war. Under the terms, Metsera shareholders will receive about $65.60 per share in cash, plus contingent value rights of up to $20.65 per share — equating to roughly $86.25 per share overall. The biotech’s board cited concerns over regulatory and antitrust risks tied to Novo Nordisk’s competing proposal as a key reason for opting for Pfizer’s offer. The acquisition gives Pfizer a foothold in the rapidly growing obesity‑treatment market, even though Metsera’s main products are still in development. Analysts estimate the global obesity‑drug market could near $150 billion in the next decade. Novo Nordisk, meanwhile, has announced it will not raise its bid, citing a focus on financial discipline and its existing pipeline. #SlimScan #GrowthStocks #CANSLIM